Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Average (2019 - 2025)

Historic Equity Average for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $660.9 million.

  • Madrigal Pharmaceuticals' Equity Average fell 1912.56% to $660.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.9 million, marking a year-over-year decrease of 1912.56%. This contributed to the annual value of $579.9 million for FY2024, which is 9241.31% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Equity Average of $660.9 million as of Q3 2025, which was down 1912.56% from $703.3 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Equity Average registered a high of $853.9 million during Q2 2024, and its lowest value of $47.1 million during Q3 2022.
  • Moreover, its 5-year median value for Equity Average was $250.3 million (2021), whereas its average is $376.8 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Equity Average tumbled by 8136.52% in 2022, and later soared by 119957.06% in 2024.
  • Madrigal Pharmaceuticals' Equity Average (Quarter) stood at $215.5 million in 2021, then tumbled by 51.73% to $104.0 million in 2022, then skyrocketed by 105.51% to $213.8 million in 2023, then skyrocketed by 258.19% to $765.8 million in 2024, then fell by 13.7% to $660.9 million in 2025.
  • Its Equity Average stands at $660.9 million for Q3 2025, versus $703.3 million for Q2 2025 and $732.5 million for Q1 2025.